ストックスクリーナーアプリを入手
8.04
1.52%
0.12
アフターアワーズ：
8.00
-0.04
-0.50%
前日終値:
$7.92
開ける：
$8.01
24時間の取引高:
801.92K
Relative Volume:
0.89
時価総額：
$488.79M
収益：
-
当期純損益:
$-156.40M
株価収益率:
-2.4513
EPS:
-3.2799
ネットキャッシュフロー:
$-151.53M
1週間 パフォーマンス:
+4.96%
1か月 パフォーマンス:
-15.28%
6か月 パフォーマンス:
+16.35%
1年 パフォーマンス:
+171.62%
1日の値動き範囲:
$7.89
$8.41
1週間の範囲:
$7.60
$8.44
52週間の値動き範囲:
$2.52
$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
名前
Kyverna Therapeutics Inc
セクター
電話
(510) 626-8331
住所
5980 HORTON STREET, EMERYVILLE
Compare KYTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
8.04 | 495.48M | 0 | -156.40M | -151.53M | -3.2799 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-20 | 開始されました | William Blair | Outperform |
| 2025-05-27 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | 開始されました | UBS | Buy |
| 2024-10-09 | 開始されました | Rodman & Renshaw | Buy |
| 2024-07-03 | 開始されました | H.C. Wainwright | Neutral |
| 2024-03-04 | 開始されました | JP Morgan | Overweight |
| 2024-03-04 | 開始されました | Leerink Partners | Outperform |
| 2024-03-04 | 開始されました | Morgan Stanley | Overweight |
| 2024-03-04 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Kyverna Therapeutics Inc (KYTX) 最新ニュース
KYTX Stock Soars After Hours: What’s Driving The Rally? - Stocktwits
KYVERNA THERAPEUTICS INC (KYTX) Stock Chart - ChartMill
KYVERNA THERAPEUTICS INC (KYTX) Stock Price & Overview - ChartMill
Kyverna Therapeutics to Participate in Upcoming September Invest - GuruFocus
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.
Kyverna vs. Vertex: Clinical-Stage Risk vs. Cash-Flow Stability in Biotech InvestingNews and Statistics - IndexBox
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? - The Motley Fool
Kyverna Therapeutics, Inc. (KYTX) Presents at Jefferies Global Healthcare Conference 2026Slideshow - Seeking Alpha
H.C. Wainwright reiterates Kyverna stock rating on autoimmune data - Investing.com UK
H.C. Wainwright reiterates Kyverna stock rating on autoimmune data By Investing.com - Investing.com Nigeria
Advancing CAR T for Drug-Free Remission in Autoimmune Disease with Kyverna Therapeutics' Dr Naji Gehchan - Bioprocess Online
KYTX Reiterates by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Kyverna Therapeutics (KYTX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
William Blair Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating - Moomoo
KYTX: Miv-cel delivers durable, drug-free remission in SPS and gMG with strong safety and market potential - TradingView
Kyverna: Buy Rating Reiterated as Emerging Clinical Profile Supports $25 Unchanged Price Target - TipRanks
Kyverna Therapeutics, Inc. Files Form 8-K Announcing Shareholder Voting Matters and Company Details (May 27, 2026) – Minichart - Minichart
Kyverna reports rheumatoid arthritis trial data at EULAR congress By Investing.com - Investing.com Nigeria
Kyverna reports rheumatoid arthritis trial data at EULAR congress - Investing.com
Kyverna Therapeutics Highlights Updated Miv-cel Data at - GlobeNewswire
Kyverna Therapeutics Stockholders Approve Directors and Auditor - TipRanks
Kyverna Therapeutics (KYTX) shareholders elect directors and ratify BDO as 2026 auditor - Stock Titan
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics - TMX Newsfile
Kyverna begins rolling BLA submission for MIV-CEL - MSN
KYTX News | KYVERNA THERAPEUTICS INC (NASDAQ:KYTX) - ChartMill
Kyverna rises on new mid-stage trial data for myasthenia gravis therapy - MSN
Kyverna Therapeutics (KYTX) director granted RSUs and options vesting in 2027 - Stock Titan
Kyverna Therapeutics (KYTX) director receives new RSU and option awards - Stock Titan
Kyverna (NASDAQ: KYTX) director granted RSUs and stock options in new Form 4 - Stock Titan
Kyverna Therapeutics (KYTX) chair has shares withheld for RSU taxes - Stock Titan
Director Aktar Mert receives Kyverna (KYTX) RSU and stock option awards - Stock Titan
KYTX: Director elections and auditor ratification approved as commercial and regulatory milestones advance - TradingView
H.C. Wainwright Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Kyverna Therapeutics appoints Greg Martini as CFO - MSN
Kyverna Therapeutics (KYTX) grants CFO Martini 325,000 stock options - Stock Titan
CFO Gregory Martini (KYTX) listed as insider in Kyverna Form 3 - Stock Titan
KYTX: Transformative CAR-T therapy for SPS nears launch, with expansion into MG and MS underway - TradingView
Kyverna Therapeutics Appoints Greg Martini as CFO to Drive Commercial Growth and Advance CAR T-Cell Therapy for Autoimmune Diseases - Minichart
Kyverna appoints Greg Martini as chief financial officer - Investing.com UK
Kyverna appoints Greg Martini as chief financial officer By Investing.com - Investing.com South Africa
Kyverna Therapeutics Appoints Greg Martini CFO Ahead of Potential Commercial Launch - citybiz
Kyverna Therapeutics Names Greg Martini CFO - Moomoo
Kyverna Therapeutics names Greg Martini as chief financial officer - marketscreener.com
Kyverna Therapeutics Names Greg Martini As Chief Financial Officer - TradingView
Kyverna Therapeutics Names Gregory Martini as New CFO - TipRanks
Kyverna Therapeutics Inc (KYTX) 財務データ
収益
当期純利益
現金流量
EPS
2.60%
0.94%
大文字化:
|
ボリューム (24 時間):